Please Wait.....
Report
Seizures Pipeline Insight Analysis Report
Market Report I 2024-08-29 I 150 Pages I EMR Inc.
Seizures Drug Pipeline Analysis 2024
Seizures, characterized by sudden and uncontrolled electrical disturbances in the brain, affect approximately 1.2% of the U.S. population, equating to around 3.4 million individuals, including both adults and children. They are a significant neurological challenge due to their unpredictable nature and the diverse ways they can manifest, often requiring multiple lines of therapy to manage effectively.
Key Takeaways
- Key players in the seizures drug pipeline market include GSK PLC, Eisai Co., Ltd.,Novartis AG, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Neurelis, Inc. These companies are at the forefront of developing cutting-edge therapies to improve patient outcomes.
- The drug pipeline for seizures includes promising candidates such as Cannabidiol Oral Solution, RWJ-333369, and Retigabine. These treatments focus on reducing seizure frequency, enhancing neuronal stability, and providing more targeted control of neurological activity, offering new hope for patients with seizure disorders.
- Regulatory agencies are encouraging the development of novel seizures treatments by providing incentives such as fast-track designations and priority reviews. This regulatory support is crucial in facilitating quicker access to new and effective therapies for patients, addressing the urgent need for more effective treatment options in this challenging condition.
Report Coverage
The Seizures treatment pipeline analysis provides an overview of recent advancements and ongoing clinical trials. The report highlights progress in developing novel therapies, including sodium channel blockers, calcium channel blockers, and GABA enhancers, aiming for effective seizure control and long-term disease management. It covers innovative approaches such as personalized medicine, which tailors treatments based on individual patient profiles and advanced monitoring technologies to optimize treatment efficacy.
Seizures Drug Pipeline Outlook
Seizures can result from various underlying causes, including genetic, structural, metabolic, and immune factors, necessitating a multifaceted treatment approach. Advancements in treatment focus on targeted therapies and personalized medicine, aiming to improve patient outcomes and quality of life by addressing the unique neurological characteristics of each patient's condition.
Advancements in treatment focus on targeted therapies and personalized medicine, aiming to improve patient outcomes and quality of life by addressing the unique genetic and molecular characteristics of this malignancy.
In 2024, significant advancements in Seizures treatment have been made. The FDA approved Ztalmy for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years and older. This approval marks the first treatment specifically for seizures related to CDD, a rare genetic disorder that causes early-onset epilepsy.
These approvals and ongoing developments underscore the dynamic and evolving nature of Seizures therapeutics, providing new treatment options and hope for improved patient outcomes.
Seizures- Pipeline Drug Profiles
Recent developments in the treatment of Seizures have introduced several promising drugs currently in clinical trials, reflecting significant advancements in the field.
- Cannabidiol Oral Solution: Cannabidiol (CBD) is an active compound derived from cannabis plants, used in the oral solution Epidiolex. It works by modulating the endocannabinoid system, which plays a role in regulating neurological processes. CBD has been shown to significantly reduce seizure frequency in patients with treatment-resistant epilepsy.
- RWJ-333369: RWJ-333369 is an investigational anticonvulsant that targets specific neurotransmitter systems to stabilize neuronal activity and prevent seizures. It is being evaluated for its potential to treat a broad range of seizure disorders, including those unresponsive to current therapies.
- Retigabine: Retigabine, also known as ezogabine, is a potassium channel opener that enhances neuronal stability by modulating potassium channels in the brain. It is used to treat partial-onset seizures and is being studied for its efficacy in other seizure types.
Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of Seizures drug based on various segmentations such as:
Analysis by Route of Administration
- Oral
The oral route of administration for seizure treatment involves medications like Cannabidiol Oral Solution, which are taken by mouth for long-term management of seizure disorders. This method offers the convenience of at-home administration, allowing patients to integrate their medication regimen into their daily routines, thereby improving adherence to therapy. Oral medications are particularly beneficial for chronic management, providing a non-invasive alternative to more immediate interventions, and are crucial for maintaining consistent blood levels of the drug to prevent seizures.
- Parenteral
Parenteral administration includes intravenous (IV) and intramuscular (IM) formulations of anticonvulsants, which are used for rapid control of acute seizures in clinical settings. This route allows for quick delivery of medication directly into the bloodstream, making it effective for emergencies where immediate seizure control is necessary. Parenteral administration is typically used in hospitals or emergency care when oral administration is not feasible.
- Others
Other delivery methods for seizure treatments include transdermal patches and buccal films. These alternative routes are designed for patients who have difficulty swallowing oral medications or require flexible dosing options. Transdermal patches provide continuous medication delivery through the skin, while buccal films allow for rapid absorption through the mucous membranes in the mouth. These methods enhance patient compliance and offer versatility in managing different types of seizures.
Analysis by Phase
According to EMR analysis, Phase III clinical trials dominate the Seizures drug pipeline. The number of Seizures drugs currently in Phase 3 clinical trials varies as new trials are continually initiated and completed. However, as of the latest data, there are over 300 ongoing Phase 3 trials for Seizures drugs worldwide. These trials involve a wide range of therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments.
- Preclinical Phase: Laboratory and animal studies to assess safety and efficacy.
- Phase I: Small-scale human trials focusing on safety and dosage.
- Phase II: Larger trials to evaluate efficacy and side effects.
- Phase III: Large-scale trials to confirm effectiveness, monitor side effects, and compare with standard treatments.
- Phase IV: Post-marketing studies to gather more information on risks, benefits, and optimal use.
Analysis by Drug Class
- Sodium Channel Blockers
Sodium channel blockers stabilize neuronal membranes by inhibiting the influx of sodium ions, which are critical for the initiation and propagation of electrical signals in the brain. By preventing abnormal electrical activity, these drugs help control seizures and are essential for managing various types of epilepsy. Examples include phenytoin and carbamazepine, which are widely used to prevent seizure episodes and maintain neuronal stability.
- Calcium Channel Blockers
Calcium channel blockers reduce the entry of calcium ions into neurons, which decreases the release of excitatory neurotransmitters. This inhibition helps control seizures by reducing neuronal excitability and preventing the excessive electrical activity that characterizes seizure disorders. Medications like ethosuximide, used primarily for absence seizures, exemplify the effectiveness of this drug class in seizure management.
- Gamma-Aminobutyric Acid (GABA) Enhancers
GABA enhancers increase the activity of gamma-aminobutyric acid, a key inhibitory neurotransmitter in the brain. By enhancing GABAergic inhibition, these drugs help prevent seizures by reducing neuronal excitability. Benzodiazepines and barbiturates, such as diazepam and phenobarbital, are common GABA enhancers used to control various seizure types, including acute and chronic seizures.
- Glutamate Receptor Antagonists
Glutamate receptor antagonists work by blocking the action of glutamate, the primary excitatory neurotransmitter in the brain. By reducing excitatory signaling, these agents help control seizures and protect against neurotoxicity. Drugs like topiramate and perampanel act on glutamate receptors, contributing to their effectiveness in managing seizures and providing an additional mechanism for seizure control.
Seizures Drug Clinical Trials Assessment- Competitive Dynamics
Here are a few notable participants involved in Seizures research and development:
These advancements represent significant steps forward in Seizures treatment, potentially offering patients more effective and less burdensome options.
GSK PLC: Headquartered in Brentford, UK, GSK is committed to advancing the treatment of neurological disorders, including seizures. The company focuses on developing innovative anticonvulsant therapies that enhance seizure control and improve the quality of life for patients with epilepsy. GSK's research emphasizes novel mechanisms of action and drug formulations, aiming to provide effective solutions for seizure management.
Eisai Co., Ltd.: Based in Tokyo, Japan, Eisai is renowned for its contributions to epilepsy treatment, particularly through its development of anticonvulsants like Fycompa (perampanel). This medication targets specific brain receptors involved in seizure activity, providing a unique approach to seizure control. Eisai continues to innovate in the field of neurology, focusing on expanding its portfolio of treatments for seizure disorders.
Novartis AG: Located in Basel, Switzerland, Novartis is actively engaged in researching new therapies for seizure disorders. The company's approach centers on precision medicine, developing targeted therapies that address the underlying causes of seizures. Novartis aims to deliver personalized treatment options that improve patient outcomes and enhance therapeutic efficacy.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: This company, part of the larger Johnson & Johnson conglomerate, is involved in creating next-generation anticonvulsants that target multiple pathways to improve seizure control. Their innovative therapies are designed to enhance the management of neurological conditions by offering new mechanisms of action and improved drug delivery systems.
Neurelis, Inc.: Based in San Diego, California, Neurelis specializes in advancing the treatment of seizure disorders through the development of novel drug delivery systems and formulations. The company focuses on therapies for acute seizure management, aiming to provide rapid and effective solutions for patients experiencing breakthrough seizures. Neurelis is dedicated to improving patient care by addressing unmet needs in seizure treatment.
Reasons To Purchase This Report
The Seizures drug pipeline analysis report offers invaluable insights into the latest advancements and future trends in Seizures treatment. It provides detailed evaluations of emerging therapies, pipeline assessment, and competitive landscape analysis, enabling informed investment decisions and strategic planning.
Key Questions Answered in the Seizures Drug Pipeline Analysis Report
- What is the current state of the seizures drug pipeline?
- How many companies are currently involved in seizures drug development?
- What is the number of drugs in Phase III and Phase IV trials for seizures?
- Which organisations are at the forefront of seizures drug research?
- What are the effectiveness and safety profiles of the drugs in the seizures pipeline?
- What opportunities and challenges exist in the seizures clinical trial landscape?
- Which companies are leading the major clinical trials for seizures drugs?
- Which regions are involved in clinical trials for seizures?
- What are the recent clinical trial results for seizures drugs?
- What are the emerging trends in seizures clinical trials?
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Seizures
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Seizures: Epidemiology Snapshot
5.1 Seizures Incidence by Key Markets
5.2 Seizures- Patients Seeking Treatment in Key Markets
6 Seizures: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Seizures: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Seizures, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Seizures Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Seizures Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Buccal Midazolam
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Carbamazepine
10.2.3 Pregabalin
10.2.4 Other Drug
11 Seizures Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 CVL-865
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Perampanel
11.2.3 Other Drugs
12 Seizures Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Topiramate
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Oxcarbazepine
12.2.3 Divalproex Sodium
12.2.4 Other Drugs
13 Seizures Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Drug 2
13.2.3 Other Drugs
14 Seizures, Key Drug Pipeline Companies
14.1 GSK PLC
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Eisai Co., Ltd.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Novartis AG
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Neurelis, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security